Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.16

€1.16

-2.150%
-0.025
-2.150%
€2.50
 
12.07.24 / Tradegate WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Akebia Therapeutics Inc. Stock

We can see a decrease in the price for Akebia Therapeutics Inc.. Compared to yesterday it has lost -€0.025 (-2.150%).
With 8 Buy predictions and 7 Sell predictions the community is currently undecided on Akebia Therapeutics Inc..
With a target price of 2 € there is a hugely positive potential of 72.41% for Akebia Therapeutics Inc. compared to the current price of 1.16 €.
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.

Pros and Cons of Akebia Therapeutics Inc. in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Akebia Therapeutics Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Akebia Therapeutics Inc. -2.150% 33.028% 13.949% 13.725% -1.024% -58.865% -
Evolus Inc 7.070% 8.163% -2.752% 61.832% 17.127% -1.852% -
Ardelyx Inc. 0.340% 10.483% -12.658% 73.505% -6.644% -20.647% -
Brainstorm Cell 14.310% 15.595% -7.226% -79.689% 59.071% -87.855% -90.672%

Comments

Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for AKBA provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -36.40%
Target price 5.552
Change
Ends at 28.03.25

Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $5.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 25.81%
Target price 3.644
Change
Ends at 29.11.24

Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Show more

News

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment: https://www.marketbeat.com/logos/articles/med_20240331142316_untitledchart-akd.jpg
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment

Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The